Miquel Vila

Miquel Vila

Vall d'Hebron Institut de Recerca

Life & Medical Sciences

Miquel Vila received his MD from the University of Barcelona (Spain) and then moved to the laboratory INSERM U289 (Prof. Y. Agid) at the Salpêtrière Hospital (Paris, France), where he obtained a Master degree (DEA) and PhD in Neuroscience from the University of Paris 6. From 1998 to 2001 he worked as a postdoctoral researcher at the laboratory of Dr. S. Przedborski at the Dept. of Neurology of Columbia University (New York, USA). In 2001, he obtained a tenure-track position as Assistant Professor of Neurology at Columbia University, a $1M-R01 NIH grant and the US permanent residency (outstanding researcher category). In December 2005, he moved back to Barcelona as an ICREA Research Professor to create and lead a new research group on Neurodegeneration at the Vall d'Hebron Research Institute, with the support of a 1.5M€ European Commission's Marie Curie Excellence Grant. He also holds positions as Associate Professor at the UAB and as Principal Investigator at the CIBERNED.

Research interests

Our research is geared toward elucidating the molecular mechanisms of neuron cell death occurring in Parkinson’s disease, the second most common neurodegenerative disorder after Alzheimer’s dementia, in order to: (i) identify biomarkers for the diagnosis, early detection, patient stratification, disease progression, prognosis or response to treatment, (ii) identify new molecular targets for potential therapeutic intervention, (iii) develop novel therapeutic strategies with disease-modifying potential for this currently incurable disease, (iv) unravel molecular pathways common to other neurodegenerative diseases.

Selected publications

– Gonzalez-Sepulveda M; Laguna A; Carballo-Carbajal I; Galiano-Landeira J; Romero-Gimenez J; Cuadros T; Parent A; Penuelas N; Compte J; Nicolau A; Guillard-Sirieix C; Xicoy H; Kobayashi J; Vila M. 2020, ‘Validation of a Reversed Phase UPLC-MS/MS Method to Determine Dopamine Metabolites and Oxidation Intermediates in Neuronal Differentiated SH-SY5Y Cells and Brain Tissue’, ACS Chem Neurosci, 11(17):2679-87.

– Alarcon-Aris D; Pavia-Collado R; Miquel-Rio L; Coppola-Segovia V; Ferres-Coy A; Ruiz-Bronchal E; Galofre M; Paz V; Campa L; Revilla R; Montefeltro A; Kordower JH; Vila M; Artigas F; Bortolozzi A 2020, ‘Anti-alpha-synuclein ASO delivered to monoamine neurons prevents alpha-synuclein accumulation in a Parkinson’s disease-like mouse model and in monkeys’, Ebiomedicine, 59:102944.

– Galiano-Landeira J, Torra A, Vila M, Bové J. ‘CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson’s disease‘. Brain, 143(12):3717-3733.

– Tolosa, E; Vila, M; Klein, C; Rascol, O. 2020, ‘LRRK2 in Parkinson disease: challenges of clinical trials’, Nat Rev Neurol, 16(2):97-107.

– Arotcarena, M-L; Dovero, S; Prigent, A; Bourdenx, M; Camus, S; Porras, G; Thiolat, M-L; Tasselli, M; Aubert, P; Kruse, N; Mollenhauer, B; Damas, IT; Estrada, C; Garcia-Carrillo, N; Vaikath, NN; El-Agnaf, OMA; Herrero, MT; Vila, M; Obeso, JA; Derkinderen, P; Dehay, B; Bezard, E. 2020, ‘Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates.’, Brain, 143(5):1462-75

– Bourdenx M et al. 2020, ‘Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates’, Science Advances, 6(20):eaaz9165.